Citigroup’s Filana Therapeutics FLNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
– Sell
-3,400
Closed -$8.02K – 5913
2024
Q4
$8.02K Sell
3,400
-49,400
-94% -$868K ﹤0.01% 5412
2024
Q3
$1.55M Buy
+52,800
New +$1.22M ﹤0.01% 2892
2024
Q1
– Sell
-49,100
Closed -$1.11M – 5828
2023
Q4
$1.11M Buy
+49,100
New +$1.04M ﹤0.01% 2743

Other funds holding FLNA

Citigroup's FLNA Position: Q3 2026 in Review

Citigroup held its Filana Therapeutics (FLNA) position steady in Q3 2026 at 19 shares worth $17. The position accounts for ﹤0.01% of the portfolio, ranked #5765.

Citigroup first reported a position in FLNA in Q2 2013 and has held it in 40 quarters since. The position peaked at $2.42M in Q3 2021. 80 funds tracked by Wall St. Rank hold FLNA as of Q3 2026.

  • Citigroup held 19 shares of Filana Therapeutics worth $17 as of Q3 2026.
  • Citigroup left its Filana Therapeutics share count unchanged in Q3 2026.
  • Filana Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #5765 holding.
  • Citigroup first reported a position in Filana Therapeutics in Q2 2013 and has held it in 40 quarters since.
  • Citigroup's Filana Therapeutics position peaked at $2.42M in Q3 2021.
  • 80 funds tracked by Wall St. Rank held Filana Therapeutics as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.